Comparison of Outreach Approaches to Increase Enrollment in a Healthy Cholesterol Study
Last updated on April 2022Recruitment
- Recruitment Status
- Completed
Inclusion Criteria
- Diabetes and or history of CVD
- Medication Possession Ratio (MPR) <80%
- LDL > or = 130 mg/dl - measured during screening
- ...
- Diabetes and or history of CVD
- Medication Possession Ratio (MPR) <80%
- LDL > or = 130 mg/dl - measured during screening
- A prescription filled for statin medication within the last 12 months
- CVS Caremark Beneficiary
Exclusion Criteria
- Co-morbidities likely to lead to death within a short-period
- Less than 18 years old
- Will not or cannot give consent
- ...
- Co-morbidities likely to lead to death within a short-period
- Less than 18 years old
- Will not or cannot give consent
- History of active or progressive liver disease or abnormal liver function tests on baseline screening
- Currently participating in another clinical trial with related aims
- Contraindication to further statin use or have suffered side effects from statins, such as myopathy
Summary
- Conditions
- Diabetes
- Type
- Interventional
- Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Other
Participation Requirements
- Age
- Between 18 years and 80 years
- Gender
- Both males and females
Inclusion Criteria
- Diabetes and or history of CVD
- Medication Possession Ratio (MPR) <80%
- LDL > or = 130 mg/dl - measured during screening
- ...
- Diabetes and or history of CVD
- Medication Possession Ratio (MPR) <80%
- LDL > or = 130 mg/dl - measured during screening
- A prescription filled for statin medication within the last 12 months
- CVS Caremark Beneficiary
Exclusion Criteria
- Co-morbidities likely to lead to death within a short-period
- Less than 18 years old
- Will not or cannot give consent
- ...
- Co-morbidities likely to lead to death within a short-period
- Less than 18 years old
- Will not or cannot give consent
- History of active or progressive liver disease or abnormal liver function tests on baseline screening
- Currently participating in another clinical trial with related aims
- Contraindication to further statin use or have suffered side effects from statins, such as myopathy
Tracking Information
- NCT #
- NCT02086539
- Collaborators
- Rutgers University
- National Institute on Aging (NIA)
- Investigators
- Principal Investigator: Kevin G Volpp, MD, PhD University of Pennsylvania
- Kevin G Volpp, MD, PhD University of Pennsylvania
Get Well Soon